Kyorin Pharmaceutical revised downward its full-year earnings forecast for the fiscal year ending March 2026, with sales of \u00a5126,257 million (a decrease of \u00a5743 million from the previous forecast), and an operating income of \u00a53,567 million (a decline of 41.5%).<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"4569","jir_company_name":"Kyorin Pharmaceutical Co., Ltd.","jir_importance":"\u2605\u2605\u2605\u2605\u2606","jir_publication_date":"2026-05-12","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/05\/4569-20260512-03.pdf","jir_short_summary":"Kyorin Pharmaceutical revised downward its full-year earnings forecast for the fiscal year ending March 2026, with sales of \u00a5126,257 million (a decrease of \u00a5743 million from the previous forecast), and an operating income of \u00a53,567 million (a decline of 41.5%).","jir_summary":"### Summary of Business Performance\nKyorin Pharmaceutical revised its full-year earnings forecast for the fiscal year ending March 2026, with sales decreasing \u00a5743 million from the previous forecast to \u00a5126,257 million. Operating income reached \u00a53,567 million, down \u00a52,533 million from the previous estimate, representing a 41.5% decline YoY. Net income also remained at \u00a53,448 million, falling \u00a51,352 million short of the forecast. The primary reasons for the sales decline include weak performance in some core products and increased one-time payments related to research and development expenses.\n\n### Outlook and Impact on Investors\nThe decrease in sales and profits presents challenges for future earnings improvement. However, the company plans to focus on research and development and the launch of new products, aiming for long-term growth. Investors should consider the short-term decline in performance while paying attention to the company's mid- to long-term growth strategies.","jir_financial_highlights":"Sales: \u00a5126,257 million (\u25b3\u00a5743 million (\u25b30.6%))\nOperating Income: \u00a53,567 million (\u25b3\u00a52,533 million (\u25b341.5%))\nNet Income Attributable to Owners of Parent: \u00a53,448 million (\u25b3\u00a51,352 million (\u25b328.2%))","jir_category":"","jir_hashtags":"#KyorinPharmaceutical, #IRFinancialResults, #JapanStocks","jir_key_figures":"Sales: \u00a5126,257 million (a decrease of \u00a5743 million from the previous forecast)\nOperating Income: \u00a53,567 million (a decrease of \u00a52,533 million from the previous forecast)\nNet Income Attributable to Owners of Parent: \u00a53,448 million (a decrease of \u00a51,352 million from the previous forecast)","jir_meta_title":"\u3010Kyorin Pharmaceutical\u30112026 Full-Year Earnings Forecast Revision \uff5c Sales \u00a5126,257 million (YoY -0.6%)","jir_meta_description":"Kyorin Pharmaceutical revised downward its full-year earnings forecast for the fiscal year ending March 2026, with sales of \u00a5126,257 million and net income of \u00a53,448 million. Attention on future strategies.","jir_og_title":"\u3010Kyorin Pharmaceutical\u30112026 Full-Year Earnings Revision \uff5c Sales \u00a5126,257 million","jir_og_description":"Kyorin Pharmaceutical revised its full-year earnings forecast for the fiscal year ending March 2026, with reductions in sales and profits. Important information for future strategies and investment decisions.","jir_og_image_url":"\/assets\/og\/company-general_ir.jpg","jir_chart_data_collection":"[]","ir_related_company":16660,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"financial_summary","footnotes":""},"sector":[],"importance":[],"class_list":["post-48158","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n